4.5 Article

Dynamics of methylated cell-free DNA in the urine of non-small cell lung cancer patients

Journal

EPIGENETICS
Volume 17, Issue 10, Pages 1057-1069

Publisher

TAYLOR & FRANCIS INC
DOI: 10.1080/15592294.2021.1982511

Keywords

Biological variation; biomarker; cancer detection; cfDNA; circadian variation; non-small cell lung cancer; urine; DNA methylation

Funding

  1. Cancer Center Amsterdam Foundation
  2. Edli Foundation
  3. Weijerhorst Foundation

Ask authors/readers for more resources

This study investigated the circadian variation of urinary cfDNA abundance and methylation levels of cancer-associated genes in NSCLC patients. It found that men had significantly lower cfDNA concentrations and the variability in cfDNA levels between and within subjects was comparable with an ICC of 0.49. The study also found that the reproducibility of methylation markers varied considerably, ranging from 0.14 to 0.74, emphasizing the importance of collecting multiple samples per patient to improve test reproducibility.
High levels of methylated DNA in urine represent an emerging biomarker for non-small cell lung cancer (NSCLC) detection and are the subject of ongoing research. This study aimed to investigate the circadian variation of urinary cell-free DNA (cfDNA) abundance and methylation levels of cancer-associated genes in NSCLC patients. In this prospective study of 23 metastatic NSCLC patients with active disease, patients were asked to collect six urine samples during the morning, afternoon, and evening of two subsequent days. Urinary cfDNA concentrations and methylation levels of CDO1, SOX17, and TAC1 were measured at each time point. Circadian variation and between- and within-subject variability were assessed using linear mixed models. Variability was estimated using the Intraclass Correlation Coefficient (ICC), representing reproducibility. No clear circadian patterns could be recognized for cfDNA concentrations or methylation levels across the different sampling time points. Significantly lower cfDNA concentrations were found in males (p=0.034). For cfDNA levels, the between- and within-subject variability were comparable, rendering an ICC of 0.49. For the methylation markers, ICCs varied considerably, ranging from 0.14 to 0.74. Test reproducibility could be improved by collecting multiple samples per patient. In conclusion, there is no preferred collection time for NSCLC detection in urine using methylation markers, but single measurements should be interpreted carefully, and serial sampling may increase test performance. This study contributes to the limited understanding of cfDNA dynamics in urine and the continued interest in urine-based liquid biopsies for cancer diagnostics.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available